What is Odyssey Therapeutics' IPO valuation target?

Odyssey Therapeutics is targeting an initial public offering valuation of up to $809.9 million.

How much money does Odyssey Therapeutics plan to raise from its IPO?

The company plans to raise up to $238.3 million from its initial public offering.

On which stock exchange will Odyssey Therapeutics be listed?

Odyssey Therapeutics intends to list on the Nasdaq Capital Market.

Home / Business and Economy / Odyssey Therapeutics Aims for $809.9M IPO

Odyssey Therapeutics Aims for $809.9M IPO

4 May

•

Summary

Odyssey Therapeutics targets an $809.9 million valuation.
The company plans to raise up to $238.3 million.
The biotech firm intends to list on Nasdaq Capital Market.

Odyssey Therapeutics Aims for $809.9M IPO

Biopharmaceutical company Odyssey Therapeutics has announced its intention to pursue an initial public offering (IPO) in the United States, targeting a valuation of up to $809.9 million. The company is preparing to raise a significant amount, seeking to secure as much as $238.3 million.

This fundraising effort involves offering 13.2 million shares, with pricing set between $16 and $18 per share. The U.S. IPO market is exhibiting early indications of recovery, having experienced its most active April in more than four years. This trend suggests a potential increase in new listings in the upcoming months.

Odyssey Therapeutics has chosen the Nasdaq Capital Market for its public debut, where it will trade under the ticker symbol 'ODTX'. Key financial institutions, including J.P. Morgan, TD Cowen, and Cantor, are serving as underwriters for this offering.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.